Ten numbers in the abstract
Where each one falls
Where it lands on the map
the abstract, start to end
Finally, the HbA1c level was 0.4 ± 0.07% for Drug A and 0.9 ± 0.2% for Drug B.
For weight, the MDs were 0.9 ± 1.4 kg for Drug A and 6.7 ± 1.6 kg for Drug B.
… LDL cholesterol reductions were 22.4 ± 5.6 mg/dL for Drug A and 31.1 ± 4.9 mg/dL for Drug B.
… also decreased, with reductions of 46.2 ± 11.4 mg/dL in the Drug A …
… HDL cholesterol levels increased by 17.0 ± 3.2 mg/dL for Drug A and 25.2 ± 2.0 mg/dL for Drug B.
… profiles, total cholesterol decreased by 18.3 ± 4.7 mg/dL in the Drug A group …
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
HbA1cDrug A (Metformin) vs baseline
−0.40
HbA1cDrug B (Empagliflozin) vs baseline
−0.90
WeightDrug A (Metformin) vs baseline
0.9
LDL cholesterolDrug A (Metformin) vs baseline
−22.4
TriglyceridesDrug A (Metformin) vs baseline
−46.2
HDL cholesterolDrug A (Metformin) vs baseline
17.0
WeightDrug B (Empagliflozin) vs baseline
6.7
Total cholesterolDrug A (Metformin) vs baseline
−18.3
LDL cholesterolDrug B (Empagliflozin) vs baseline
−31.1
HDL cholesterolDrug B (Empagliflozin) vs baseline
25.2
MetforminSGLT2 inhibitorsGlycemic controlBody weight & compositionLipids
1 / 3